Pulmonx Corp. is a medical technology company that specializes in developing minimally invasive solutions for patients with severe lung diseases. The company was founded in 1998 by a group of leading experts in the field of interventional pulmonology and respiratory medicine. Pulmonx is headquartered in Redwood City, California, USA.
The primary focus of Pulmonx is the treatment of chronic obstructive pulmonary disease (COPD) and severe emphysema. The company's flagship product is called the Zephyr Endobronchial Valve System. This innovative device is designed to improve lung function and quality of life for patients with severe emphysema by redirecting airflow to healthier lung tissue. The Zephyr Valve is inserted through a bronchoscope and implanted in the airways to block off the damaged parts of the lung, allowing the healthier areas to function more efficiently.
Pulmonx has made significant strides in the field of interventional pulmonology. The Zephyr Valve System has received regulatory approvals in many countries and has been used in thousands of patients worldwide. It has been shown to improve lung function, exercise capacity, and quality of life for eligible patients with severe emphysema. Pulmonx continues to invest in research and development to advance its product portfolio and expand treatment options for patients with severe lung diseases.
Pulmonx's commitment to innovation and improving the lives of patients with severe lung diseases has earned it recognition within the medical community. The Zephyr Valve System has received multiple awards and accolades for its impact on patient care. Additionally, Pulmonx has forged partnerships with renowned medical organizations to drive research, education, and awareness about the benefits of interventional pulmonology.